Body Vision Medical, a medical device company specializing in augmented real-time imaging, announced that it has received clearance from the US Food and Drug Administration to market LungVision, a novel imaging system that enables accurate real-time navigation and lesion localization during bronchoscopic procedures.

LungVision, the first product based on the Body Vision platform, demonstrated outstanding results through multicenter clinical trials in the US Utilizing a sophisticated augmented reality approach, LungVision allows physicians to plan, visualize, and track endobronchial tools and radiolucent lesions in real time. LungVision's synergistic imaging merges intraoperative fluoroscopy with pre-operative high resolution imaging, such as computed tomography.

"Body Vision developed unique technology that combines the intelligence of navigation with the simplicity of fluoroscopy," says D. Kyle Hogarth, MD, FCCP associate professor of Medicine, Director of Bronchoscopy at the University of Chicago and one of the first LungVision users in North America. "It enables effective localization and enhanced biopsy of lung lesions, upgrading the standard methods used in our daily practice."

Body Vision chief executive officer Dorian Averbuch added, "We are thrilled to introduce the Body Vision platform to the medical community. We envision that in the near future, the LungVision system will revolutionize the way physicians diagnose and treat peripheral lung lesions."

The first clinical experience with the LungVision System will be presented by Sean Stoy, MD, University of Chicago Medical Center, at the American Thoracic Society meeting, held May 19-24 at the Walter E. Washington Convention Center in Washington, DC. The presentation will take place on May 21, 2017 from 2:15-4:15 pm as a part of the rapid poster discussion session A110, "Advances of the thoracic oncologic diagnostics".